Lifeline Biotechnologies Provides Information To The Public And Its Shareholders
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
by admin | Feb 21, 2018 | NewsFebruary 27, 2018 Cyrcadia, Inc. (“CI”) extends its thanks and appreciation in your interest and support of our endeavors. We are taking this opportunity to provide an update, as well as apprise you of upcoming expectations. License and Cooperation Agreement with Cyrcadia Asia (“CA”) – Status Earlier in 2017 CI entered into an Agreement with CA, whereby CA assumed the responsibility and funding of the design, development and delivery of a scalable, commercializable iTBra™ system including upgraded hardware and the full suite of application software as well as automation of our proprietary Artificial Intelligence Analytics. The estimated cost of development with Jabil and Mobile Now is approximately $1.2 to $1.5 million US. As such, the agreement calls for CA to provide timely reporting and status of product development including timelines, milestones and dates of completion and delivery of product (market readiness, product volume availability and delivery terms and schedules). Many strides have been made in the evolution of the relationship as CA has established its operations, initial staffing and funding. Both CI and CA are in a mode of cooperation, as called for by the Agreement and, presently, both entities are to hold routine meetings where comprehensive updating and reporting will be delivered to CI, enabling implementation of our business, operations and marketing plans. We will be reporting the outcomes of that meeting to move forward on our ability to commercialize the iTBra™ system this year. Given the above, we would like to update on the internal operations that will allow for CI to “hit the ground running” upon product delivery. Status of Product Development and Manufacturing Under CA’s...
Welcome to Lifeline Biotechnologies Inc. (LLBO) Board!!!
Clinical Trial
In Progress - To Be Completed
** Funding for Clinical Trial
** Vendor delivery of testing materials
Completed for Clinical Trial
** Protocol for testing accepted
** Internal Review Board (IRB) approved
** Contract with hospital executed
Prospective Partner
** Stanford University's Canary Research
Research in blood genomics
MastaScope
The Mastascope is an ultraslim, hand held endoscope designed to enter the breast nipple via one of its milk ducts, thus permitting the physician to visualize the interior aspects of the breast. Because many cancers actually begin within an individual milk duct, these intraductal tumors are visualized easily and can be biopsied. This product has been used in leading breast centers in the United Kingdom and other countries with great success. Lifeline has obtained a CE mark for marketing and distribution in Europe.
OvaScope
Lifeline has developed and tested an ultraslim endoscope to directly visualize the ovarian surface in the search for cancer. This is of great advantage to physicians, because neither MRI, X-Ray nor Ultrasonography can provide accurate assessments of subtle surface changes. Initial reports of clinical usage have been encouraging.
About $LLBO - Lifeline Biotechnologies, Inc.
About Lifeline Biotechnologies:
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV. LLBO has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer. Three “Proof of Concept” clinical trials of over 500 women have been completed and three patents (one hardware, two software) have been awarded.
Safe Harbor:
This publication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.
http://www.firstwarningsystems.com/ became Cyrcadia Health http://cyrcadiahealth.com/
http://www.lbti.com
$LLBO is Cyrcadia's largest shareholder at approximately 40%.
Transfer Agent
OTC Corporate Transfer Service Co.
52 Maple Run Drive
Jericho, NY 11753
Share Structure
| Shares Outstanding | 3,026,680,967 | a/o Sep 30, 2014 |
| Float | 650,000,000 | a/o Jun 30, 2009 |
| Authorized Shares | 4,950,000,000 | a/o Sep 30, 2014 |
| Par Value | 0.001 |
Company Information About Lifeline Biotechnologies:
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV. LLBO has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer. Three “Proof of Concept” clinical trials of over 500 women have been completed and three patents (one hardware, two software) have been awarded. http://www.lbti.com
About Cyrcadia Health
Cyrcadia Health founded in 2008, is based in Reno, Nev. The Cyrcadia Health product line is a device and software service that detects breast tissue abnormalities leading to health risk assessment and management including early breast cancer identification. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. Cyrcadia Health technology is exclusively licensed for development, manufacturing and marketing worldwide from Lifeline Biotechnologies, Inc (OTC Market: LLBO). Cyrcadia Health is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. Cyrcadia Health is preparing to apply for a Euro CE Mark to market in the European Union and Asia Pacific markets. See Cyrcadia Health video, “Breast Cancer Tumor Progression” at http://www.cyrcadiahealth.com/
iTBra in the News
ABC 7 News - February 5, 2015
HIGH-TECH BRA COULD HELP DETECT BREAST CANCER IN SHORTER AMOUNT OF TIME ABC 7 News - February 5, 2015 http://abc7.com/health/high-tech-bra-helps-detect-breast-cancer-faster/506633/ HIGH-TECH BRA HELPS DETECT BREAST CANCER ABC 7 News - January 30, 2015 http://abc7news.com/496449/ Good Monring America apperance coming.... Quote from the March 12, 2015 PR
http://finance.yahoo.com/news/lifeline-biotechnologies-llbo-q1-2015-171609507.html They also interviewed Rob Royea (Cyrcadia's President) for a feature story on Good Morning America expected to air in the next coming months.
https://mobile.twitter.com/RobRoyea/status/564872820635627520
Could a Bra Actually Detect Breast Cancer?
By Smithsonian Magzine
http://www.smithsonianmag.com/innovation/could-a-bra-actually-detect-breast-cancer-180954612/?utm_source=twitter.com&no-ist
Documentary Movie: Detected coming....
Funded by Cisco Detected Trailer...
Detected trailer on Cisco's facebook page
https://www.facebook.com/video.php?v=10153675766948032&pnref=story
Video